Effect of Anti-CD14 Antibody on Experimental Periodontitis Induced by Porphyromonas gingivalis Lipopolysaccharide

Pao-Li Wang¹*, Mari Oido-Mori², Takeo Fujii², Yusuke Kowashi², Masanori Kikuchi³, Yasushi Suetsugu¹, Junzo Tanaka³, Yasutaka Azuma¹, Mitsuko Shinohara¹ and Kiyoshi Ohura¹

¹Department of Pharmacology, Osaka Dental University, 8-1 Kuzuhahanazono-cho Hirakata 573-1121, Japan
²Department of Periodontology and Endodontology, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kamazawa, Ishikari-Tobetsu 061-0293, Japan
³National Institute for Materials Science, Advanced Materials Laboratory, Bioceramics Research Group, 1-1 Namiki Tsukuba 305-0044, Japan

Received September 25, 2001 Accepted March 19, 2002

ABSTRACT—The lipopolysaccharide (LPS) released by Porphyromonas gingivalis, a Gram-negative bacterium found in the periodontal pockets of patients with periodontitis, induces bone resorbing activity in vivo. We previously showed that a receptor for LPS on human gingival fibroblasts and gingival epithelial cells is CD14. In this study, we established a mouse model of experimental periodontitis by applying a P. gingivalis LPS solution to the buccal region of mice. P. gingivalis LPS-induced bone resorption and interleukin-6 production in the gingival tissues were significantly inhibited by pretreatment with anti-CD14 antibody for 5 weeks prior to LPS treatment. This result suggests that anti-CD14 antibody may be usable as a prototype for the development of drugs for the treatment of periodontal disease.

Keywords: Lipopolysaccharide, CD14, Periodontal disease, Experimental periodontitis, Animal model

Periodontal disease comprises a group of infections that lead to inflammation of the gingiva and destruction of periodontal tissues; and in severe cases, they are accompanied by loss of alveolar bone with eventual exfoliation of teeth (1). Oral microbes are involved in the progression of periodontal disease that eventually causes tooth loss. Specifically, Gram negative bacteria have become widely recognized as the periodontopathic bacteria (2). Lipopolysaccharide (LPS), a component of the bacterial outer membrane, is the pathogenetic factor in a wide variety of periodontopathic bacteria (3, 4). For this reason, numerous studies have examined the immune response of periodontal tissue cells upon exposure to periodontopathic LPS. When periodontopathic bacteria proliferate in periodontal pockets, it is suggested that LPS is amply released, causing immunocytes such as macrophages and fibroblasts to steadily synthesize inflammatory cytokines including interleukin (IL)-1 and IL-6. These cytokines, in turn, aggravate inflammation, destroy periodontal tissues, and induce alveolar bone resorption (5 – 11).

Since Mouton et al. reported that patients with adult periodontitis have a higher serum level of immunoglobulin G (IgG) antibodies against P. gingivalis than control individuals (12), many investigators have reported that patients with periodontitis have elevated levels of antibodies against sonicates of P. gingivalis in both the serum and gingival crevicular fluid. P. gingivalis is primarily found in deep periodontal pockets and, especially, in active sites of infection (13). P. gingivalis lipopolysaccharide (P-LPS) may also play an important role in the pathogenic mechanism leading to inflammation of the gingiva and alveolar bone loss in periodontal diseases. We have focused our attention on P-LPS (7 – 11) and P. gingivalis protease (14 – 16) and the immune response of gingival fibroblasts and gingival epithelial cells, which comprise most of the human periodontal tissue. We previously suggested that the receptor for P-LPS on gingival fibroblasts (7) and gingival epithelial cells is CD14 (11). To elucidate the mechanism of inflammatory bone resorption induced by P-LPS, using an in vitro culture system, we identified the sequence of events from P-LPS stimulation to bone resorption. Upon stimulation by P-LPS, fibroblasts produce IL-6, which in turn activates osteoclasts and eventually causes bone adsorption (9).
It is very important to develop a strategy for preventing periodontal disease. Having established an animal model of periodontitis by treating mice with P-LPS, we sought to examine if anti-CD14 antibody (Ab) inhibits bone resorption. In this study, we show that anti-CD14 Ab inhibits alveolar bone resorption of the maxilla and IL-6 production in P-LPS induced periodontitis in mice.

MATERIALS AND METHODS

P-LPS and anti-CD14 Ab

P-LPS was prepared as previously described (17). Briefly, LPS was extracted from acetone-dried cells of *P. gingivalis* by the phenol-water method (17) and then purified by ultracentrifugation six times at 105,000 × g at 4°C for 16 h each and RNase treatment. Mouse anti-human CD14 monoclonal antibody (anti-CD14 Ab) (IgG1, clone MEM-18) was purchased from Monosan (Am Uden, Netherlands). P-LPS-induced IL-6 production in mice gingival fibroblasts was inhibited by anti-CD14 Ab, and the binding of LPS to the cells was abrogated by the antibody (data not shown). Thus, this antibody reacted to mice.

Animals and experimental design

The protocol employed here meets the guidelines of The Japanese Pharmacological Society. All efforts were made to minimize animal suffering and to reduce the number of animal used. Seven-week-old, male, specific pathogen-free C3H/HeN mice were purchased from Sankyo Laboratory Service Co. (Tokyo). All animals weighed between 20 and 22 g, and were divided into five groups (n = 5 in each group). The Group A mice were treated with P-LPS for 10 weeks. The Group B mice were treated with P-LPS + anti-CD14 Ab for 10 weeks. The Group C mice were pretreated with anti-CD14 Ab for 4 weeks and then treated with LPS + anti-CD14 Ab for 10 weeks. The Group D mice were pretreated with anti-CD14 Ab for five weeks, and then treated with LPS + anti-CD14 Ab for 10 weeks. The control group was not treated with P-LPS nor anti-CD14 Ab. The experimental schedules of the four experimental groups are shown in Fig. 1. To remove NaN₃, the antibody was dialyzed, and it was concentrated to a 1 mg/ml. The reagent [1 mg/ml of P-LPS dissolved in distilled water (D.W.) and/or 1 mg/ml of anti-CD14 Ab dissolved in D.W.] was swabbed onto the buccal region of each mouse in the quiescent state for 5 min with a swab, once every two days. The specified level of anti-body concentration was determined based on the concentrations used in our previous culture experiments of P-LPS stimulation of the IL-6-producing system (7). The approximate total amount of LPS or anti-CD14 Ab that was applied to each mouse during one application was 50 μl. During the experimental period, all mice were given demineralized food and water ad lib. All mice were weighed weekly. The mice in the four experimental groups were sacrificed on the day after the last day of treatment by general anesthesia using Nembutal (Abbott Laboratories, North Chicago, IL, USA). The control mice were sacrificed at the end of 15 weeks.

![Fig. 1](image-url)  
**Fig. 1.** Treatment schedules of LPS with or without anti-CD14 antibody in the mice of Groups A, B, C and D. The control mice were not treated with LPS or anti-CD14 antibody. The upward arrow represents the time point at which LPS or anti-CD14 antibody treatment was started.
Measurement of the level of alveolar bone adsorption

For preparation of the bone specimen, the left maxilla was excised from the mouse. After a 5-day fixation in a solution of 10% neutral formalin (Wako, Osaka) plus sodium hypochlorite (Wako), it was spread out. After neutralization and washing in 3% hydrogen peroxide in water, the soft tissue was mechanically removed from the left maxilla specimen under a stereoscopic microscope (Olympus, Tokyo). The tissue was sectioned. The sections were dyed in 5% basic fuchsin aqueous solution after they had dried, in order to clarify the cement at each animal boundary as a measurement of alveolar bone adsorption. The level of alveolar bone adsorption was determined using the procedures described by Sallay et al. (18) and Crawford et al. (19). The distance (mm) from the cement of one enamel boundary to the top of the alveolar bone was measured at seven locations in the first, second and third molars of the left maxilla of a mouse. A diagram of the first, second and third molars of the left maxilla on the maxilla primary mesial root buccal palate side is shown. The distance between the second and third molars of the left maxilla on the maxilla primary mesial root buccal palate side is shown. The distance (mm) from the cement of one enamel boundary to the top of the alveolar bone was measured at seven locations in the first, second and third molars using a Paek Scale Lupe (Masuda Co., Osaka) on the maxilla primary mesial root buccal palate side, as shown in Fig. 2.

The amount of IL-6 in the gingival tissues

Gingival samples were biopsied from gingival tissues on the mouse. Biopsy specimens were dissected into 1 mm in diameter and then washed by phosphate-buffered saline (PBS) (pH 7.4). Gingival samples were plated onto 96 well culture plates (Costar, Cambridge, MA, USA) with RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 10% heat-inactivated fetal calf serum (FCS) (Gibco), 2 mM L-glutamine (Gibco), 100 U penicillin (Gibco) and 100 mg/ml streptomycin (Gibco), in a humidified atmosphere of 5% CO₂ at 37°C for 48 h. The amount of IL-6 in 100 μl of the culture supernatant on gingival samples culture was measured using an enzyme-linked immunosorbent assay (ELISA), according to the manufacturer’s instructions. The ELISA kit was purchased from Wako.

Statistical analyses

All data are expressed as the mean ± S.E.M. Statistical analyses were performed by the Scheffe test; P<0.05 was considered significant.

RESULTS

The weight of the mice in each experimental group did not significantly differ from that of the control group at each 1-week time point (Fig. 3). Therefore, application of anti-CD14 Ab and/or LPS does not affect the body weight of these laboratory animals.

Figure 4 shows representative photographs of the left maxilla of a mouse in each experimental and control group under microscopic observation. A greater degree of bone resorption was observed in the mice in Groups A, B, and C in comparison with that in the control mice. The degree of bone resorption in the Group D mice was less than that in the mice of Groups A, B, and C, although it was greater than that in the control mice.

Figure 5 shows the level of alveolar bone adsorption in each group. The level of alveolar bone adsorption in the A, B, C, D and control groups, was 0.47 ± 0.03 mm, 0.48 ± 0.05 mm, 0.47 ± 0.06 mm, 0.34 ± 0.08 mm and 0.12 ± 0.04 mm, respectively. The level of alveolar bone adsorption in the Group A mice which had been treated with LPS alone for 10 weeks, was significantly larger than that in the Group D mice (P<0.05). The level of alveolar bone adsorption among the mice in Group A, B or C did not significantly differ. The level of alveolar bone adsorption in the control mice was significantly smaller than that in the Group A, B, C or D mice (P<0.05). Treatment with anti-CD14 Ab alone over 10 weeks did not affect the level of alveolar bone adsorption (data not shown). The control mice also showed a small degree of alveolar bone adsorption; these data are within the normal range of bone adsorption. From these results (Figs. 4 and 5), treatment with P-LPS alone for 10 weeks enhanced alveolar bone adsorption.

The level of IL-6 was produced by P-LPS. The level of IL-6 in the control was significantly smaller than that in the group of pretreatment for 4 and 5 weeks (P<0.05). Anti-CD14 Ab inhibited P-LPS IL-6 production in the gingival tissues. The level of IL-6 in the periodontal tissue started to decrease gradually in the third week of the pretreatment (Fig. 6).

Thus, pretreatment with anti-CD14 Ab for 5 weeks prior to P-LPS and anti-CD14 Ab treatment for 10 weeks inhibited P-LPS-induced bone adsorption and IL-6 production in the gingival tissues.
DISCUSSION

Many basic and clinical studies support the concept that human periodontitis is a disease caused by several types of Gram-negative bacteria that mainly exist in dental plaque (1). In the pathology of periodontal disease, it has been clarified that periodontal disease is the end result of the host immune response to LPS, rather than the result of one-sided invasion of a periodontopathic bacterium. The specificity of various pathogen fungi in causing periodontal disease was proven in an animal experiment system in which individual bacterial cells isolated from a human periodontitis lesion were infected in laboratory animals (20–24). The animal models of periodontal disease were recently reviewed by Weinberg and Bral (25). Many of these animals were infected by means of a bacterium-soaked silk ligature or the gavaging of bacterium. In this study, we established a mouse model of experimental periodontitis by applying a periodontopathic bacterium solution to the buccal region of mice. Namely, as P-LPS has been strongly implicated as one of the major causative agents of periodontal disease, we established a mouse model of experimental periodontitis with P-LPS. Mice that were stimulated with P-LPS for 10 weeks showed enhanced bone resorption.

In periodontitis lesions, the human gingival fibroblasts
and gingival epithelial cells in the oral cavity, which are the major constituents of gingival connective tissue, may interact directly with bacteria and bacterial products including LPS. It is, therefore, suggested that these cells play

Fig. 4. Morphological changes of bone formation after completion of LPS treatment for 10 weeks (A), LPS and anti-CD14 antibody treatment for 10 weeks (B), or pre-treatment with anti-CD14 antibody for 4 weeks (C) or 5 weeks (D), and then treatment with LPS and anti-CD14 antibody for 10 weeks. Photographs of the left maxilla of a representative mouse in each group are shown.

Fig. 5. Level of alveolar bone adsorption (mm) in the four experimental groups and the control group. Each bar represents the mean ± S.E.M. (n = 5). *P<0.05.
important roles in the host responses of patients with periodontitis to LPS. Upon stimulation by oral black-pigmented bacteria such as *P. gingivalis* and their components including LPS, gingival fibroblasts and gingival epithelial cells produce various inflammatory cytokines including IL-1, IL-6 and IL-8 (7, 11, 26, 27). These cytokines may, in turn, initiate and exacerbate periodontal inflammatory diseases. The present study showed P-LPS induced gingival tissues to produce IL-6 in a mouse model of experimental periodontitis.

CD14 is one of several receptors for LPS and is expressed predominantly on the surface of monocytes, macrophages, and neutrophils (28 – 30). Shapira et al. (31) showed that P-LPS stimulates human monocytes in a CD14-dependent manner. In addition, we (7, 11) and other groups (30, 31) have demonstrated that the signal transduction pathway stimulated by P-LPS in human gingival fibroblasts and gingival epithelial cells, acts through CD14. We recently found that LPS stimulation of human gingival fibroblasts induces protein tyrosine phosphorylation of several intracellular proteins including extracellular signal-regulated kinase 2 (ERK2) (7). These events were suppressed by anti-CD14 Ab (7). Furthermore, we demonstrated in vitro that P-LPS stimulates the production of IL-6, which in turn activates osteoclasts (9). Thus, cytokines play a crucial role as mediators of inflammation in periodontal disease. More recently, we demonstrated in vitro that IL-10 inhibits the inflammatory response through the IL-10 receptor on gingival fibroblasts in P-LPS-initiated periodontal disease (10). Furthermore, several studies have shown that various types of antibiotics are effective for the treatment of chronic inflammatory disease. Golub et al. (32) suggested that a non-antimicrobial action of tetracycline inhibits both the production of gingival matrix metalloproteinase and bone loss in *P. gingivalis*-induced periodontitis in rats. These studies suggest that an antibiotic(s), cytokine(s) or anti-CD14 Ab may be able to prevent the development of periodontal disease by inhibiting P-LPS-stimulated expression of inflammatory cytokines such as IL-1 and IL-6 that are involved in the pathogenesis of periodontal disease. Our present study demonstrates that P-LPS stimulates bone resorption and that anti-CD14 Ab inhibits P-LPS-induced bone resorption and the level of IL-6 in the gingival tissues when administered for 5 weeks prior to P-LPS treatment in an animal model of periodontitis.

As shown in the present study, P-LPS-stimulated periodontitis in mice was not completely inhibited by anti-CD14 Ab. This suggests that upon P-LPS stimulation, another pathway(s) in addition to the CD14 pathway, is involved in the development of experimental periodontitis in mice, because LPS also binds to receptors other than CD14 on immunocytes such as monocytes, macrophages, and neutrophils and fibroblasts in the gingiva. On the other hand, we have already reported that anti-CD14 Ab inhibits IL-6, which is an inflammatory cytokine produced by P-LPS stimulants in human gingival fibroblasts (7). Therefore, in the present study, we expected to find that P-LPS and anti-CD14 Ab jointly inhibit bone resorption and

**Fig. 6.** Level of IL-6 in the gingival tissues. The concentration of IL-6 in the culture supernatant was measured by ELISA. Each bar represents the mean ± S.E.M. (n = 5). *P<0.05.
cortactin inhibits the development of P-LPS induced periodontitis in vivo (9). From this study, this suggests that the inflammatory cytokine accelerates bone resorption in vitro (9). From this study, this suggests that the inflammatory cytokine such as IL-6 can be inhibited by the antibody. Although we have not yet reached a definite explanation of the result, one possibility would be that a long-term storage of anti-CD14 Ab in periodontal tissues contributes in some way to the inhibition of bone resorption and cytokine. Another possibility would be that the anti-CD14 Ab, causing LPS-like effects, had B cell produce some anti-LPS antibody. Thus, the mechanism of the residual bone resorption after anti-CD14 Ab treatment, remains to be elucidated.

This study is the first to demonstrate that anti-CD14 Ab inhibits the development of P-LPS induced periodontitis in mice. Our results raise the possibility that anti-CD14 Ab can be used as a prototype for developing remedial drugs for the treatment of periodontal disease.

Acknowledgments

We are grateful to Dr. Katsuhide Sonoda (ILCS, Hokkaido University, Japan) for his valuable advice on this study. This study was presented at the 73rd Annual Meeting of The Japanese Pharmacological Society, March 24, 2000, Yokohama, Japan.

REFERENCES

22 Genco CA, Kapeczynski DR, Cutler CW, Arko RJ and Arnold


